Who are ABX464 Repeated dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): adapalene gel, 0.3%, Topical Adapalene Gel 0.1%, Adapalene Gel, 0.1%, Adapalene Lotion Vehicle, Adapalene 0,1% cream, Differin 0.3% Topical Gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abx464-repeated-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ABX464 Repeated dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABX464 Repeated dose (ABX464 Repeated dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule. Area: Immunology.

phase 1 Small molecule RARγ Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ABX464 Repeated dose (ABX464 Repeated dose) — Abivax S.A.. ABX464 is a small molecule antagonist of RARγ

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABX464 Repeated dose TARGET	ABX464 Repeated dose	Abivax S.A.	phase 1	Small molecule	RARγ
adapalene gel, 0.3%	adapalene gel, 0.3%	Galderma R&D	marketed	Retinoid (third-generation)	Retinoic acid receptors (RARγ, RARα, RARβ)
Topical Adapalene Gel 0.1%	Topical Adapalene Gel 0.1%	University of Louisville	marketed	Retinoid	Retinoic acid receptor gamma (RARγ)
Adapalene Gel, 0.1%	Adapalene Gel, 0.1%	Galderma R&D	marketed	Retinoid (third-generation)	Retinoic acid receptors (RARα, RARβ, RARγ)
Adapalene Lotion Vehicle	Adapalene Lotion Vehicle	Galderma R&D	phase 3	Retinoid (third-generation)	Retinoic acid receptors (RARγ, RARα, RARβ)
Adapalene 0,1% cream	Adapalene 0,1% cream	Dr.dr.Irma Bernadette, SpKK (K)	phase 3	Retinoid	Retinoic acid receptor gamma (RARγ)
Differin 0.3% Topical Gel	Differin 0.3% Topical Gel	Aleor Dermaceuticals Limited	phase 3	Retinoid (third-generation)	Retinoic acid receptor gamma (RARγ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small molecule class)

Pfizer · 3 drugs in this class
Akorn, Inc. · 1 drug in this class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 drug in this class
Health Research, Inc. · 1 drug in this class
Imperial College London · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 drug in this class
Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
UroGen Pharma Ltd. · 1 drug in this class
Abivax S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABX464 Repeated dose — Competitive Intelligence Brief. https://druglandscape.com/ci/abx464-repeated-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing